Product category:
Microbiology
News Release from: Warnex | Subject: Pharmacogenetic services
Edited by the Laboratorytalk Editorial
Team on 25 January 2007
Pharmacogenetic services for
Schering-Plough
Warnex announces that its medical laboratories division will develop new pharmacogenetic assays and serve as a central laboratory for several clinical studies of Schering-Plough Canada
"Pharmacogenetic assays allow the correlation of different responses to drugs with genetic diversity and/or mutations, improving the overall process of drug development," said Mark Busgang, president and CEO of Warnex "In 2006, Warnex acquired Pro-DNA Diagnostics, a laboratory offering genetic testing services, in order to enter the pharmacogenetics market
This article was originally published on Laboratorytalk on 21 Mar 2006 at 8.00am (UK)
Related stories
Quantitative PCR test for food testing
Warnex has announced the launch of a quantitative test for Campylobacter for use with the real-time PCR-based Warnex rapid pathogen detection system
Warnex signs up US service lab, AmeriSci Bio-Chem
AmeriSci Bio-Chem, a leading scientific service laboratory based in Midlothian, Virginia, will offer real-time PCR pathogen testing services using the Warnex rapid pathogen detection system
"These new projects with Schering-Plough Canada validate our strategy to develop our presence in this growing market".
Pharmacogenetics helps to predict whether a patient will have a good response to a drug, a bad response to a drug or no response at all.
According to the US Food and Drug Administration Center for Drug Evaluation and Research, over two million adverse drug reactions (ADRs) occur yearly leading to more than 100,000 deaths yearly.
ADRs are one of the leading causes of hospitalisation and death, ahead of pulmonary disease, diabetes, Aids and pneumonia in the United States.
By employing pharmacogenetic studies in drug development, companies can increase the likelihood of a positive study result by matching patients who are more likely to respond or alternatively not more likely not to have an adverse event.
Warnex Medical Laboratories will provide pharmacogenetic and molecular biology services during Schering-Plough Canada's clinical trials for drugs related to the treatment of different types of cancer and infectious diseases.
Warnex Medical Laboratories focuses on genetic and biochemical testing for the healthcare industry.
The division performs testing in a wide range of clinical specialties, including endocrinology, haematology, infectious diseases, obstetrics/gynaecology, and oncology, and has extensive expertise in genetic testing for human identification, molecular medicine, and pharmacogenetics.
• Warnex: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
